Abstract
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic neurites and neurofibrillary pathology, which eventually result in the degeneration of neurons and subsequent dementia. In 1999, international interest in a new therapeutic approach to the treatment of AD was ignited following transgenic mouse studies that indicated that it might be possible to immunise against the pathological alterations in Aβ that lead to aggregation of this protein in the brain. A subsequent phase I human trial for safety, tolerability and immunogenicity using an active immunisation strategy against Aβ had a positive outcome. However, phase ILA human trials involving active immunisation were halted following the diagnosis of aseptic meningoencephalitis in 6% of immunised subjects. Research into immunisation strategies involving transgenic AD mouse models has subsequently been refocused to determine the mechanisms by which plaque clearance and reduced memory deficits are attained, and to establish safer therapeutic approaches that may reduce potentially harmful brain inflammation. The vigour of international research on immunotherapy for AD provides significant hope for a strong therapeutic lead for the escalating number of individuals who will develop this otherwise incurable condition.
Similar content being viewed by others
References
Vickers JC, Dickson TC, Adlard PA, et al. The cause of neuronal degeneration in Alzheimer’s disease. Prog Neurobiol 2000; 60(2): 139–65
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82(4): 239–59
Benzing WW, Ikonomovic MD, Brady DR, et al. Evidence that transmitter-containing dystrophic neurites precede paired helical filament and Alz50 formation within senile plaques in the amygdala of nondemented elderly and patients with Alzheimer’s disease. J Comp Neurol 1993; 334(2): 176–91
Masliah E, Mallory M, Hansen L, et al. An antibody against phosphorylated neurofilaments identifies a subset of damaged association axons in Alzheimer’s disease. Am J Pathol 1993; 142(3): 871–82
Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimer’s disease: I. Progressive changes in states of paired helical filaments and neurofilaments. Brain Res 1996; 739(1–2): 79–87
Dickson TC, King CE, McCormack GH, et al. Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer’s disease. Exp Neurol 1999; 156(1): 100–10
Dickson TC, Chuckowree JA, Chuah MI, et al. Novel Alzheimer’s disease pathology reflects variable neuronal vulnerability and demonstrates the role of b-amyloid plaques in neurodegeneration. Neurobiol Dis 2005; 18(2): 286–95
Braak H, Braak E. Neuropil threads occur in dendrites of tanglebearing nerve cells. Neuropathol Appl Neurobiol 1988; 14(1): 39–44
Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992; 42 (3 Pt 1): 631–9
Lue LF, Brachova L, Civin WH, et al. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. J Neuropathol Exp Neurol 1996; 55(10): 1083–8
Knowles RB, Gomez-Isla T, Hyman BT. Aβ associated neuropil changes: correlation with neuronal loss and dementia. J Neuropathol Exp Neurol 1998; 57(12): 1122–30
Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 1999; 45(3): 358–68
Loo DT, Copani A, Pike CJ, et al. Apoptosis is induced by βamyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A 1993; 90(17): 7951–5
Ivins KJ, Bui ETN, Cotman CW. β-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol Dis 1998; 5(5): 365–78
Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Aβl–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95(11): 6448–53
Wang SS-S, Becerra-Arteaga A, Good TA. Development of a novel diffusion-based method to estimate the size of the aggregated Aβ species responsible for neurotoxicity. Biotechnol Bioeng 2002; 80(1): 50–9
Sola S, Castro RE, Laires PA, et al. Tauroursodeoxycholic acid prevents amyloid-β peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med 2003; 9(9–12): 226–34
Caraci F, Chisari M, Frasca G, et al. Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against β-amyloid toxicity. Brain Res 2005; 1047(1): 30–7
Estus S, Tucker HM, Van Rooyen C, et al. Aggregated amyloidβ protein induces cortical neuronal apoptosis and concomitant “apoptotic” pattern of gene induction. J Neurosci 1997; 17(20): 7736–45
Hartley DM, Walsh DM, Ye CP, et al. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999; 19(20): 8876–84
Vickers JC, Chin D, Edwards A-M, et al. Dystrophic neurite formation associated with age-related β amyloid deposition in the neocortex: clues to the genesis of neurofibrillary pathology. Exp Neurol 1996; 141(1): 1–11
Metsaars WP, Hauw J-J, Van Weisem ME, et al. A grading system of Alzheimer disease lesions in neocortical areas. Neurobiol Aging 2003; 24(4): 563–72
Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993; 75(6): 1039–42
Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994; 13(1): 45–53
Beyreuther K, Masters CL. Alzheimer’s disease: the ins and outs of amyloid-beta. Nature 1997; 389(6652): 677–8
Hardy J, Duff K, Hardy KG, et al. Genetic dissection of Alzheimer’s disease and related dementias: amyloid and its relationship to tau. Nat Neurosci 1998; 1(5): 355–8
Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer’s disease. J Biol Chem 1996; 271(31): 18295–8
Sandbrink R, Beyreuther K. Unraveling the molecular pathway of Alzheimer’s disease: research about presenilins gathers momentum. Mol Psychiatry 1996; 1(6): 438–44
Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10 Suppl.: S2–9
Lemere CA, Blusztajn JK, Yamaguchi H, et al. Sequence of deposition of heterogeneous amyloid β-peptides and Apo E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996; 3(1): 16–32
Brion JP. The neurobiology of Alzheimer’s disease. Acta Clinica Belgica 1996; 51(2): 80–90
Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F βamyloid precursor protein. Nature 1995; 373(6514): 523–7
Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996; 274(5284): 99–102
Borchelt DR, Ratovitski T, van Lare J, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997; 19(4): 939–45
Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997; 94(24): 13287–92
Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998; 4(1): 97–100
Moechars D, Dewachter I, Lorent K, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999; 274(10): 6483–92
Janus C, Chishti MA, Westaway D. Transgenic mouse models of Alzheimer’s disease. Biochim Biophys Acta 2000; 1502(1): 63–75
Mucke L, Masliah E, Yu G-Q, et al. High-level neuronal expression of Aβl–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000; 20(11): 4050–8
Chishti MA, Yang D-S, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Bio Chem 2001; 276(24): 21562–70
Blanchard V, Moussaoui S, Czech C, et al. Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice. Exp Neurol 2003; 184(1): 247–63
Higgins GA, Jacobsen H. Transgenic mouse models of Alzheimer’s disease: phenotype and application. Behav Pharm 2003; 14(5–6): 419–38
Richards JG, Higgins GA, Ouagazzal A-M, et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 2003; 23(26): 8989–9003
Cheng IH, Palop JJ, Esposito LA, et al. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 2004; 10(11): 1190–2
Kawasumi M, Chiba T, Yamada M, et al. Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer’s disease in aged mice. Euro J Neurosci 2004; 19(10): 2826–38
Brodaty H, Ames D, Boundy KL, et al. Pharmacological treatment of cognitive deficits in Alzheimer’s disease. Med J Aust 2001; 175(6): 324–7
Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer’s disease: the way forward. Drugs 1997; 53(5): 752–68
Lessring MA, Farris W, Chang AY, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003; 40(6): 1087–93
Bergamaschini L, Rossi E, Pizzimenti S, et al. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaque and beta-amyloid accumulation in a mouse model of Alzheimer’s disease. J Neurosci 2004; 24(17): 4181–6
Chauhan NB, Siegel GJ, Feinstein DL. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res 2004; 29(10): 1897–911
Marr RA, Guan H. Neprilysin regulates amyloid beta peptide levels. J Mol Neurosci 2004; 22(1–2): 5–11
Arbel M, Yacoby I, Solomon B. Inhibition of amyloid precursor protein processing by β-secretase through site-directed antibodies. Proc Natl Acad Sci U S A 2005; 102(21): 7718–23
Singer O, Marr RA. Targeting BACE1 siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005; 8(10): 1343–2349
Asai M, Hattori H, Iwata N, et al. The novel β-secretase inhibitor KMI-429 reduces amyloid β peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006; 96(2): 533–40
McLaurin J, Kierstead ME, Brown ME, et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 2006; 12(7): 801–8
Yamada T, Sasaki H, Furuya H, et al. Complementary DNA for the mouse homolog of the human amyloid beta protein precursor. Biochem Biophys Res Commun 1987; 149(2): 665–71
Check E. Nerve inflammation halts trial for Alzheimer’s drug. Nature 2002; 415(6871): 462
Orgogozo J-M, Gilman S, Dartigues J-F, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003; 61(1): 46–54
Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400(6740): 173–7
Sigurdsson EM, Scholtzova H, Mehta PD, et al. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer’s disease associated pathology in transgenic mice. Am J Pathol 2001; 159(2): 439–47
Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A 2003; 100(4): 2023–8
Das P, Howard V, Loosbrock N, et al. Amyloid-β immunization effectively reduces amyloid deposition in FcRg−/− knock-out mice. J Neurosci 2003; 23(24): 8532–8
Lemere CA, Spooner ET, LaFrancois J, et al. Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol Dis 2003; 14(1): 10–8
Zhang J, Wu X, Qin C, et al. A novel recombinant adenoassociated virus vaccine reduces behavioural impairment and β-amyloid plaques in a mouse model of Alzheimer’s disease. Neurobiol Dis 2003; 14(3): 365–79
Hara H, Monsonego A, Yuasa K, et al. Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer’s disease. J Alzheimers Dis 2004; 6(5): 483–8
Kim H-D, Kong F-K, Cao Y, et al. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid βprotein and GM-CSF reduces amyloid load in the brain. Neurosci Lett 2004; 370(203): 218–23
Schiltz JG, Salzer U, Mohajeri MH, et al. Antibodies form a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer’s disease. J Mol Med 2004; 82(10): 706–14
Bowers WJ, Mastrangelo MA, Stanley HA, et al. HSV amplicon-mediated Aβ vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol Aging 2005; 26(4): 393–407
Buttini M, Masliah E, Barbour R, et al. β-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease. J Neurosci 2005; 25(40): 9096–101
Frenkel D, Maron R, Burt DS, et al. Nasal vaccination with a proteasome-based adjuvant and glatiramer acetate clears βamyloid in a mouse model of Alzheimer disease. J Clin Invest 2005; 115(9): 2423–33
Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer’s disease. Nat Med 2000; 6(8): 916–9
Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci 2002; 22(18): 7873–8
Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res 2003; 74(1): 353–7
Lombardo JA, Sterns EA, McLellan ME, et al. Amyloid-β antibody treatment leads to rapid normalization of plaqueinduced neuritic alterations. J Neurosci 2003; 23(34): 10879–83
Wilcock DM, DiCarlo G, Henderson D, et al. Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 2003; 23(9): 3745–51
Bussière T, Bard F, Barbour B, et al. Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 2004; 165(3): 987–95
Horikoshi Y, Mori T, Maeda M, et al. Aβ N-terminal-end specific antibody reduced β-amyloid in Alzheimer-model mice. Biochem Biophys Res Commun 2004; 325(2): 384–7
Oddo S, Billings L, Kesslak JP, et al. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43(3): 321–32
Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004; 1(1): 24
Brendza RP, Bacskai BJ, Cirrito JR, et al. Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 2005; 115(2): 428–33
Chauhan NB, Siegel GJ. Efficacy of anti-Aβ antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci Letters 2005; 375(3): 143–7
Hartman RE, Izumi Y, Bales KR, et al. Treatment with an amyloid-β antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer’s disease. J Neurosci 2005; 25(26): 6213–20
Yamamoto N, Yokoseki T, Shibata M, et al. Suppression of Aβ deposition in brain by peripheral administration of Fab fragments of anti-seed antibody. Biochem Biophys Res Commun 2005; 335(1): 45–7
Levites Y, Pritam D, Price RW, et al. Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 2006; 116(1): 193–201
Lemere CA, Beierschmitt A, Iglesias M, et al. Alzheimer’s disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004; 165(1): 283–97
Li S-B, Wang H-Q, Lin X, et al. Specific humoral immune responses in rhesus monkeys vaccinated with the Alzheimer’s disease-associated β-amyloid 1–15 peptide vaccine. 2005; 118(8): 660–4
Duff K, Eckman C, Zehr C, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383: 710–3
Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003; 39(3): 409–21
Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2001; 408(6815): 982–5
Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer’s disease. J Neurosci 2002; 22(15): 6331–5
Billings LM, Oddo S, Green KN, et al. Intraneuronal Aβ causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron 2005; 45(5): 675–88
Lee EB, Leng LZ, Zhang B, et al. Targeting Aβ oligomers by passive immunization with a conformation selective monoclonal antibody improves learning and memory in APP transgenic mice. J Bio Chem 2006; 281(7): 4292–9
Wilcock DM, Munireddy SK, Rosenthal A, et al. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration. Neurobiol Dis 2004; 15(1): 11–20
Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 2002; 5(5): 452–7
Jensen MT, Mottin MD, Cracchiolo JR, et al. Lifelong immunization with human β-amyloid (1–42) protects Alzheimer’s transgenic mice against cognitive impairment throughout aging. Neurosci 2005; 130(3): 667–84
Klyubin I, Walsh DM, Lemere CA, et al. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nature Med 2005; 11(5): 556–61
Spooner ET, Desai RV, Mori C, et al. The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol. Vaccine 2002; 21(3–4): 290–7
Locksley RM, Heinzel FP, Sadik MD, et al. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann Inst Pasteur Immunol 1987; 138(5): 744–9
Koller MF, Mohajeri MH, Huber M, et al. Active immunization of mice with an Aβ-Hsp70 vaccine. Neurodegener Dis 2003; 1(1): 20–8
Kutzler MA, Cao C, Bai Y, et al. Mapping of immune response following wild-type and mutant Abeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA class II transgenic mice. Vaccine 2006; 24(21): 4630–9
Monsonego A, Imitola J, Petrovic S, et al. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer’s disease. PNAS 2006; 103(13): 5048–53
Senior K. Dosing in phase II trial of Alzheimer’s vaccine suspended. Lancet Neurol 2002; 1(1): 3
Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 2005; 64(1): 94–101
Gilman S, Koller M, Black RS, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64(9): 1553–62
Lee M, Bard F, Johnson-Wood K, et al. Aβ42 immunization in Alzheimer’s disease generates Aβ N-terminal antibodies. Ann Neurol 2005; 58(3): 430–5
Nicoll JAR, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003; 9(4): 448–52
Ferrer I, Rovira MB, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer’s disease. Brain Pathol 2004; 14(1): 11–20
Masliah E, Hansen L, Adams A, et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer’s disease. Neurology 2005; 64(1): 129–31
Lee EB, Leng LZ, Lee VM-Y, et al. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer’s amyloidosis. FEBS Letters 2005; 579(12): 2564–8
Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. Neurobiol Dis 2005; 25(3): 629–36
Herber DL, Roth LM, Wilson D, et al. Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 2004; 190(1): 245–53
Carty NC, Wilcock D, Rosenthal A, et al. Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflammation 2006; 10(3): 1–11
Morgan D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochem Int 2006; 49(2): 190–4
DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 2001; 98(15): 8850–5
DeMattos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer’s disease. J Neurochem 2002; 81(2): 229–36
Banks WA, Terrell B, Farr SA, et al. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer’s disease. Peptides 2002; 23(12): 2223–6
Deane R, Sagare A, Hamm K, et al. IgG-assisted age-dependent clearance of Alzheimer’s amyloid β peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005; 25(50): 11495–503
Qu B, Rosenberg RN, Li L, et al. Gene vaccination to bias the immune response to amyloid-β peptide as therapy for Alzheimer disease. Arch Neurol 2004; 61(12): 1859–64
He Y, Sun S-H, Chen RW, et al. Effects of epitopes combination and adjuvants on immune responses to anti-Alzheimer disease DNA vaccines in mice. Alzheimer Dis Assoc Disord 2005; 19(4): 171–7
Maier M, Seabrook TJ, Lazo ND, et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer’s disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006; 26(18): 4717–28
Okura Y, Miyakoshi A, Kohyama K, et al. Nonviral Aβ DNA vaccine therapy against Alzheimer’s disease: long-term effects and safety. Proc Natl Acad Sci U S A 2006; 103(25): 9619–24
Zurbriggen R, Amacker M, Kammer AR, et al. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer’s disease. J Mol Neurosci 2005; 27(2): 157–66
Acknowledgements
The authors are supported by the National Health and Medical Research Council, the Royal Hobart Hospital Research Foundation and the Tasmanian Masonic Medical Research Foundation. The authors have no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Woodhouse, A., Dickson, T.C. & Vickers, J.C. Vaccination Strategies for Alzheimer’s Disease. Drugs Aging 24, 107–119 (2007). https://doi.org/10.2165/00002512-200724020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200724020-00003